New combo shows promise for Hard-to-Treat breast cancer
Disease control
Completed
This study tested a combination of two drugs—pembrolizumab (an immunotherapy) and olaparib (a PARP inhibitor)—in 14 people with advanced breast cancer that has a BRCA mutation or similar DNA repair problem. The goal was to see if the combo could shrink or stabilize tumors. The ca…
Phase: PHASE2 • Sponsor: Yuan Yuan • Aim: Disease control
Last updated May 13, 2026 16:03 UTC